Pharmafile Logo
Pharmafocus logo
Advanced Search

Roche

Showing 15 posts of 704 posts found.

Roche shows improved survival rates in new treatment for untreated acute myeloid leukaemia

March 24, 2020
Manufacturing and Production Cancer, Roche, acute myeloid leukamia

Roche has announced that its clinical trials for Venclexta/Venclyzto combination with azacitidine have met its primary endpoints of overall survival …

News
shutter

COVID-19: Gilead freezes compassionate access to remdesivir due to “overwhelming demand”, BMS and Lilly delay new study launches

March 24, 2020
Manufacturing and Production, Medical Communications, Research and Development Bristol-Myers Squibb, Eli Lilly, Gilead, Roche, cornavirus, pharma

As national governments continue to ramp up measures to contain the ongoing COVID-19 coronavirus outbreak, so too are pharma and …

News

FDA gives emergency authorisation to first coronavirus tests

March 17, 2020
Manufacturing and Production, Sales and Marketing FDA, Roche, US, coronavirus

The coronavirus crisis in the US has thus far been characterised by a lack of testing within its population. This …

News

Venclyxto combo scores European approval for previously untreated chronic lymphocytic leukaemia

March 13, 2020
Medical Communications, Sales and Marketing AbbVie, European Commission, Roche, Venclyxto, pharma

The European Commission has moved to authorise AbbVie and Roche’s B-cell lymphoma-2 (BCL-2) inhibitor Venclyxto (venetoclax) when used in combination …

News

China approves Roche’s Actemra to fight severe complications stemming from coronavirus

March 5, 2020
Sales and Marketing Actemra, China, Roche, coronavirus, pharma

China has moved to authorise Roche’s Actemra (tocilizumab) as a treatment for severe complications from contracting the COVID-19 coronavirus in …

News
nice_new_london_office_internal_3_web

NICE rejects Roche’s Polivy combo in relapsed or refractory diffuse large B-cell lymphoma

February 26, 2020
Manufacturing and Production, Research and Development, Sales and Marketing NHS, NICE, Polivy, Roche

It has been revealed that UK drug watchdog NICE has chosen to reject Roche’s Polivy (polatuzumab vedotin), used alongside rituximab …

News
alzheimers

Roche’s experimental Alzheimer’s drug does not meet primary endpoint in clinical trials

February 10, 2020
Sales and Marketing Alzheimer's, Roche, roche Alzheimer

Roche has said its experimental drug, gantenerumab, did not meet its primary endpoint in people who have an inherited form …

News

Roche’s Tecentriq falls short as an adjuvant monotherapy in muscle-invasive urothelial cancer

January 24, 2020
Medical Communications, Sales and Marketing Cancer, Roche, pharma, tecentriq, trial failure

Roche has released an update on the development of its immunology Tecentriq (atezolizumab), making it known that the drug failed …

News
roche__tree

Roche’s risdiplam hits main goal in infants with spinal muscular atrophy

January 23, 2020
Research and Development Roche, pharma, risdiplam, spinal muscular atrophy

Roche has announced the success of its survival motor neuron-2 (SMN2) splicing modifier risdiplam in a new trial investigating its …

News

China approves Roche cancer drug Kadcyla

January 22, 2020
Business Services China, Roche, breast cancer, cancer treatment, oncology

China has approved the import of Roche’s drug for breast cancer, just after it recently won expanded approval in the …

News
roche__tree

EU approval for Roche’s Polivy combo in relapsed/refractory B-cell lymphoma

January 21, 2020
Manufacturing and Production, Sales and Marketing Cancer, Polivy, Roche, lymphoma, pharma

The European Commission has awarded conditional marketing approval to Roche’s Polivy (polatuzumab vedotin), it has been revealed.

News
roche

Roche’s Tecentriq combo boosts progression-free survival in previously untreated BRAF V600 mutation-positive advanced melanoma

December 16, 2019
Manufacturing and Production, Research and Development, Sales and Marketing Roche, melanoma, pharma, tecentriq

Roche has lifted the curtain on new Phase 3 data for its immunotherapy Tecentriq (atezolizumab), confirming that the therapy, when …

News
roche

Roche’s subcutaneous Perjeta/Herceptin combo proves non-inferior to IV formulation in HER2-positive early breast cancer

December 12, 2019
Research and Development Cancer, Herceptin, Perjeta, Roche, breast cancer, pharma

New Phase 3 data from Roche has shown that its subcutaneously-delivered formulation of Perjeta (pertuzumab) and Herceptin (trastuzumab), in combination …

News
tecentriq

Roche’s Tecentriq combo scores FDA approval in non-small cell lung cancer

December 4, 2019
Research and Development, Sales and Marketing FDA, NSCLC, Roche, pharma, tecentriq

Roche’s immunotherapy Tecentriq (atelizumab) has chalked up another approval from the FDA, this time in combination with the chemotherapy Abraxane …

News

Roche’s satralizumab shows promise at Phase 3 in neuromyelitis optica spectrum disorder

December 2, 2019
Research and Development, Sales and Marketing Roche, pharma, satralizumab

Roche has presented new data on its interleukin-6 (IL-6) inhibitor satralizumab in the treatment of neuromyelitis optica spectrum disorder (NMOSD), …

News

Latest content

FDA approves Amgen’s Imdelltra for extensive-stage small cell lung cancer

May 17, 2024

AstraZeneca shares results from phase 3 trial of COVID-19 prevention drug

May 17, 2024

GSK pledges £45m to Fleming Initiative to fight AMR

May 16, 2024

NeuroSense partners with PhaseV on upcoming phase 3 ALS trial

May 16, 2024

AstraZeneca adds new heart failure target through collaboration with BenevolentAI

May 15, 2024